Immucell Corp (ICCC) Stock Price

ICCCStock

$9.94+62.42%52W

Market Cap$90.28M

P/E—

PEG Ratio—

Div yield—

Beta0.54

ICCC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)39.59%

Price vs S&P 500 (4W)-11.51%

VGM Score58.73

P/CF (Annual)40.57x

Book Value / Share (Quarterly)$3.22

P/TBV (Annual)2.06x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.18%

Cash Flow / Share (Quarterly)$0.37

Price vs S&P 500 (YTD)48.80%

Gross Margin (TTM)42.59%

Net Profit Margin (TTM)-1.82%

EPS (TTM)$-0.06

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-0.06

Revenue Growth (5Y)12.50%

EPS (Annual)$-0.12

ROI (Annual)-2.88%

Gross Margin (Annual)41.40%

Net Profit Margin (5Y Avg)-11.76%

Cash / Share (Quarterly)$0.75

P/E Basic Excl Extra (TTM)25.81x

Revenue Growth QoQ (YoY)28.39%

ROA (Last FY)-2.45%

Revenue Growth TTM (YoY)9.64%

EBITD / Share (TTM)$0.27

ROE (5Y Avg)-8.65%

Operating Margin (TTM)-0.55%

Cash Flow / Share (Annual)$0.14

P/B Ratio3.45x

P/B Ratio (Quarterly)1.97x

Net Income / Employee (Annual)$-14,200

EV / Revenue (TTM)3.42x

Net Interest Coverage (TTM)-2.07x

ROA (TTM)-1.22%

EPS Growth QoQ (YoY)33.21%

EV / EBITDA (TTM)42.60x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)4.26x

Quick Ratio (Quarterly)2.44x

3-Month Avg Trading Volume0.03M

52-Week Price Return62.42%

EV / Free Cash Flow (Annual)83.53x

P/E Incl Extra (TTM)25.81x

Revenue / Employee (TTM)$410,100

Tangible BV / Share (Quarterly)$2.99

P/S Ratio (Annual)3.63x

Asset Turnover (Annual)0.65x

52-Week High$12.10

Operating Margin (5Y Avg)-10.04%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-21.02%

Tangible BV CAGR (5Y)-0.80%

26-Week Price Return51.52%

Quick Ratio (Annual)1.82x

13-Week Price Return0.40%

Total Debt / Equity (Annual)0.34x

Current Ratio (Quarterly)4.82x

Enterprise Value$102.31M

Revenue / Share Growth (5Y)7.56%

Asset Turnover (TTM)0.67x

Book Value / Share Growth (5Y)-5.24%

Revenue / Employee (Annual)$378,700

Inventory Turnover (Annual)1.98x

Pretax Margin (Annual)-3.72%

Cash / Share (Annual)$0.42

3-Month Return Std Dev49.32%

Gross Margin (5Y Avg)35.95%

Net Income / Employee (TTM)$-7,500

EBITDA CAGR (5Y)3.43%

EBITDA Interim CAGR (5Y)59.76%

ROE (Last FY)-3.84%

Net Interest Coverage (Annual)-0.75x

EPS Basic Excl Extra (Annual)$-0.12

P/FCF (TTM)19.49x

Receivables Turnover (TTM)9.91x

EV / Free Cash Flow (TTM)30.31x

Total Debt / Equity (Quarterly)0.30x

EPS Incl Extra (TTM)$-0.06

Receivables Turnover (Annual)7.69x

ROI (TTM)-1.43%

P/S Ratio (TTM)3.35x

Pretax Margin (5Y Avg)-11.72%

Revenue / Share (Annual)$3.06

Tangible BV / Share (Annual)$2.99

Price vs S&P 500 (52W)43.86%

P/E Ratio (TTM)25.81x

Year-to-Date Return61.63%

5-Day Price Return1.02%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-5.23%

Net Profit Margin (Annual)-3.76%

Month-to-Date Return-11.33%

Cash Flow / Share (TTM)$-0.47

EBITD / Share (Annual)$0.23

Operating Margin (Annual)-2.14%

LT Debt / Equity (Annual)0.28x

P/CF (TTM)22.44x

ROI (5Y Avg)-6.10%

P/E Excl Extra (TTM)25.81x

LT Debt / Equity (Quarterly)0.24x

EPS Basic Excl Extra (TTM)$-0.06

P/TBV (Quarterly)2.06x

P/B Ratio (Annual)2.06x

Inventory Turnover (TTM)2.14x

Pretax Margin (TTM)-1.75%

Book Value / Share (Annual)$2.99

Price vs S&P 500 (13W)-1.55%

Beta0.54x

P/FCF (Annual)81.99x

Revenue / Share (TTM)$3.31

ROE (TTM)-1.88%

52-Week Low$4.52

vGradeC

gGradeB

mGradeB

vgmGradeC

ICCC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2020	Feb 22, 2021	-$0.04	$0.03	+175.00%(+$0.07)
Q3 2020	Nov 12, 2020	-$0.08	-$0.04	+50.00%(+$0.04)
Q2 2020	Aug 12, 2020	-$0.10	-$0.11	-10.00%(-$0.01)
Q1 2020	May 13, 2020	—	-$0.02	—

ICCC Analyst Recommendations

Sep 2021

Oct 2021

Nov 2021

Dec 2021

4.14

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
ICCCImmucell Corp	C	B	B	$9.94
IDXXIdexx Laboratories Inc	D	B	C	$554.99
LNTHLantheus Holdings, Inc	C	B	B	$100.77
CLDXCelldex Therapeutics, Inc	F	F	B	$39.12
NEOGNeogen Corp	C	C	B	$11.66
NTLAIntellia Therapeutics, Inc	D	D	C	$12.87
QDELQuidelOrtho Corporation Common Stock	C	C	C	$14.74
ACHVAchieve Life Sciences, Inc.	F	F	A	$8.10
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	$7.12
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	F	$7.67
MYGNMyriad Genetics Inc	B	C	D	$3.16
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	$4.13
QCLSQ/C Technologies, Inc. Common Stock	C	—	F	$2.35
TRIBTrinity Biotech plc	B	D	F	$9.68
BMRABIOMERICA INC	B	D	C	$2.14
VNRXVolitionRx Limited	B	A	F	$0.45
CDIOCardio Diagnostics Holdings Inc. Common stock	—	C	D	$1.85
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	$2.82
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	B	$0.02

About Immucell Corp

ImmuCell Corp develops and commercializes health products for the dairy and beef cattle industries. The company operates two business segments: Scours (First Defense, a USDA-regulated product to prevent disease in newborn calves) and Mastitis (Re-Tain, an FDA-regulated treatment for subclinical mastitis in dairy cows). The Scours segment generates the majority of company revenue.